Business Wire

Loop Energy and Fraunhofer ISE Testing Demonstrates the Potential of Innovative eFlow™ Flow Field Design to Increase Hydrogen Production in Electrolyzers

Share

Loop Energy (TSX: LPEN), a designer and manufacturer of hydrogen fuel cell solutions, has completed third-party validation of the use of its patented eFlow technology in PEM electrolyzers. In partnership with Fraunhofer USA, testing was conducted by the German Fraunhofer Institute for Solar Energy Systems ISE, and has demonstrated a fuel cell architecture with trapezoid flow field design can enhance temperature uniformity. When incorporated into conventional PEM electrolysis cells, this bipolar plate architecture demonstrates it can increase hydrogen production. Loop Energy is now seeking industry partners to develop a full-scale electrolyzer prototype for commercial validation.

Results show that eFlow architecture creates a more stable and uniform operating environment in the PEM water electrolysis test cells compared to conventional flow fields with parallel channels, resulting in greater hydrogen production and improved efficiency. Testing also shows the enhanced uniform operating environment should have a beneficial impact on durability.

“Results from the validation process show that the new flow field technology has the potential to surpass typical levels of hydrogen production that we see in the industry today and supports green hydrogen production to become increasingly economically viable,” said Fraunhofer ISE Head of Department Chemical Energy Storage, Dr. Tom Smolinka. “The difference we have seen from current electrolyzer performance with conventional parallel flow field is that the adapted design appears to create more uniform temperature distribution could make it an enabling technology for some of the advanced materials needed to really increase the economics of electrolyzers and green hydrogen.”

Encouraged by the results, Loop Energy and Fraunhofer ISE are inviting expressions of interest from potential industry partners. Interested parties will partner with the two companies in designing and manufacturing an electrolyzer prototype to verify eFlow’s benefits for producing hydrogen on a commercial scale. All expressions of interest can be directed to Loop Energy Chief Commercial Officer, George Rubin.

“The completion of third-party validation is an important milestone for Loop Energy as we explore how eFlow can transform the hydrogen production sector,” said Loop Energy President & CEO, Ben Nyland. “We’re extremely pleased to partner with Fraunhofer ISE and draw on their long-lasting experience in cell and stack design for PEM water electrolysis. The results have been encouraging, and we’re excited to begin the search for strategic partners to support us as we innovate electrolyzer technology.”

Currently, Loop Energy’s proprietary eFlow technology is applied in its fuel cell products to offer unmatched levels of fuel efficiency. Its tapering channel design enables eFlow to provide improved uniform current density and increases gas velocity to deliver superior thermal and water management. With the new discovery that eFlow can benefit hydrogen production efficiency, it expands the patented technology’s potential use across the hydrogen energy vertical.

Global demand for hydrogen production is projected to grow by more than US$1 trillion by 20501. As a result, both new and existing hydrogen producers are searching for a competitive advantage to meet rising demand.

Ben Nyland will share details of this development at CERAWeek on March 6 and 7 alongside Thomas Schuelke, president of Fraunhofer USA, which also acts as project partner. In addition, Dr. Tom Smolinka and Loop Energy Chief Scientist, Dr. Sean Mackinnon will present the technical results at Hannover Messe on April 17. Requests for meetings at either event can be coordinated with Ethan Hugh.

Loop Energy’s management team will share more details on its end of year financial results call on March 30. Call details can be found on Loop Energy’s website.

About Fraunhofer ISE

The Fraunhofer-Gesellschaft, based in Germany, is the world's leading organization for application-oriented research. With its focus on key technologies of relevance to the future and on the exploitation of results in business and industry, it plays a central role in the innovation process. As a guide and stimulus for innovative developments and scientific excellence, it helps shape our society and our future. Founded in 1949, the organization currently operates 76 institutes and research facilities in Germany. More than 30,000 employees, most of them trained in the natural sciences or engineering, produce the annual research volume of 2.9 billion euros. Of this, 2.5 billion euros is spent on contract research. Further information: www.ise.fraunhofer.de/en

About Fraunhofer USA

Fraunhofer USA, Inc., a legally independent US affiliate founded by Fraunhofer-Gesellschaft, is an R&D organization working with industry, universities, and state and federal governments on contract R&D projects. Fraunhofer is in the high-tech problem-solving business and utilizes world class scientific and engineering expertise to engage in complex R&D projects across many different disciplines. Through Fraunhofer USA, U.S. clients can connect to the 79 research units throughout the U.S. and Germany with over 30,000 employees, predominantly scientists and engineers. www.fraunhofer.org

About Loop Energy Inc.

Loop Energy is a leading designer and manufacturer of hydrogen fuel cell systems targeted for the electrification of commercial vehicles, including light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop Energy’s products feature the company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow is designed to enable commercial customers to achieve performance maximization and cost minimization. Loop Energy works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop Energy is driving towards a zero-emissions future, visit www.loopenergy.com.

Forward Looking Warning

This press release contains forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Particularly, statements regarding the Company’s expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operate is forward-looking information, including without limitation, purchase orders, cost reduction, profitability and revenue targets; our future growth prospects and business outlook including without limitation the expected demand for our products, the allocation of resources and funds, the expected timeline for profitability, the planned growth of our customer base and the expected growth of our operations globally. Forward-looking information is based on a number of assumptions (including without limitation assumptions with respect the current and future performance of the Company’s products, growth in demand for the Company’s products, the Company’s ability to execute on its strategy, achieve its targets and progress existing and future customers through the Customer Adoption Cycle in a timely way, and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward-looking information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Loop Energy Investor Inquiries:
Natalie Arseneau | Tel: +1 604.222.3400 Ext. 418 | investors@loopenergy.com

Loop Energy Business Inquiries:
George Rubin | Tel: +1.604.828.8185 | grubin@loopenergy.com

Loop Energy Media Inquiries:
Ethan Hugh | Tel: +1 604.306.4277| ethan.hugh@loopenergy.com
Lucas Schmidt | Tel: +1.778.791.8756 | lucas.schmidt@loopenergy.com

Fraunhofer ISE Inquiries:
Dr. Tom Smolinka | Tel: +49.761.4588.5212 | tom.smolinka@ise.fraunhofer.de
Diana Bribach | Tel: +49.761.4588.2804 | diana.bribach@ise.fraunhofer.de

Fraunhofer USA Inquiries:
Elliott Sprehe | Tel: +734.927.3984 | esprehe@fraunhofer.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye